Merck: Keytruda promising in gastric cancer
(CercleFinance.com) - Merck today announced the results of the phase 3 trial (KEYNOTE-811) evaluating Keytruda, in combination with trastuzumab, fluoropyrimidine and platinum-based chemotherapy, for the first-line treatment of patients with HER2-positive, unresectable or metastatic locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
"These data emphasize the importance of KEYTRUDA, in combination with trastuzumab and chemotherapy, as a treatment option for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 with a CPS ≥1 and reinforce our commitment to continuing to explore effective therapies for difficult-to-treat gastrointestinal cancers," Dr. Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories.
These data are being presented today at the 2023 Congress of the European Society for Medical Oncology (ESMO), and are being discussed with regulatory authorities worldwide.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
"These data emphasize the importance of KEYTRUDA, in combination with trastuzumab and chemotherapy, as a treatment option for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 with a CPS ≥1 and reinforce our commitment to continuing to explore effective therapies for difficult-to-treat gastrointestinal cancers," Dr. Marjorie Green, senior vice president and head of late-stage oncology, global clinical development, Merck Research Laboratories.
These data are being presented today at the 2023 Congress of the European Society for Medical Oncology (ESMO), and are being discussed with regulatory authorities worldwide.
Copyright (c) 2023 CercleFinance.com. All rights reserved.